Equitable Holdings
EQH
$47.80
+1.70%
Equitable Holdings, Inc. is a diversified financial services company providing retirement, asset management, and wealth management solutions to individual and institutional clients. It operates through three segments: Retirement (annuities and savings products), Asset Management (via AllianceBernstein), and Wealth Management (advisory and insurance). The company holds a strong position in the retirement and insurance space, leveraging its scale and distribution network. Current investor attention centers on the company's capital return strategy, including significant share buybacks, and its ability to navigate volatile markets and regulatory changes while improving profitability.…
EQH
Equitable Holdings
$47.80
Related headlines
Investment Opinion: Should I buy EQH Today?
Rating: Buy. Thesis: EQH is a deep value play with a forward PE of 5.2x, a strong capital return program, and a Q4 earnings turnaround that, if sustained, offers significant upside. The consensus analyst rating is Overweight/Buy, and the average EPS estimate of $12.21 implies a forward PE of just 3.7x, suggesting the market is pricing in a recovery that may already be underway.
Supporting Evidence: The primary valuation metric, forward PE of 5.18x, is less than half the sector average of 12x, indicating deep undervaluation. Revenue, though down 9.5% YoY in Q4, rebounded sequentially from $1.45B to $3.28B, and gross margin improved to 88.1% from 67.3% a year ago. Free cash flow TTM is $737M, providing flexibility for buybacks. The dividend yield of 2.64% adds a income component. The stock has rallied 20.7% over the past three months, outperforming the S&P 500 by 7.1%, suggesting momentum is building.
Risks & Conditions: The biggest risks are earnings sustainability (Q4 profitability may be temporary) and the negative equity base. This Buy would downgrade to Hold if Q1 2026 earnings show a return to losses or if revenue growth remains negative. It would upgrade to Strong Buy if the company reports consistent EPS above $1.00 per quarter and provides guidance confirming the $12.21 consensus. Overall, EQH appears undervalued relative to its forward earnings potential, but the TTM losses warrant caution. The stock is a speculative value play for investors with a high risk tolerance.
Sign up to view all
EQH 12-Month Price Forecast
EQH is a high-risk, high-reward value play. The forward PE of 5.2x is deeply discounted, but the TTM losses and revenue volatility warrant caution. The Q4 2025 earnings turnaround is encouraging, but one quarter does not confirm a trend. The base case of $45-$55 is most likely, with a 50% probability, as the market will need multiple quarters of consistent profitability to re-rate the stock. The bull case (30% probability) requires sustained earnings growth and multiple expansion, while the bear case (20% probability) could materialize if the recovery falters. The stance is bullish due to the low valuation and strong cash position, but confidence is medium given the earnings uncertainty. An upgrade to high confidence would require two consecutive quarters of positive EPS and revenue growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Equitable Holdings's 12-month outlook, with a consensus price target around $62.14 and implied upside of +30.0% versus the current price.
Average Target
$62.14
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$38 - $62
Analyst target range
Only 2 analysts cover EQH, which is limited coverage for a mid-cap stock. The consensus recommendation is bullish, with all ratings being Overweight or Buy. The average estimated EPS for the current fiscal year is $12.21, with a range of $11.21 to $13.31. The average revenue estimate is $17.78 billion, with a range of $16.66 billion to $19.02 billion. Based on the current price of $45.61 and a forward PE of 5.18x, the implied upside to the average EPS target is significant, but no explicit price targets are provided. The limited coverage means the stock may be less efficiently priced, leading to higher volatility. Recent ratings from major firms (Morgan Stanley, Wells Fargo, UBS, JP Morgan, Barclays) have all been Overweight or Buy, with no downgrades, indicating strong institutional confidence. The wide EPS range ($11.21 to $13.31) suggests moderate uncertainty about the earnings recovery trajectory. The lack of a consensus price target makes it difficult to quantify upside, but the bullish ratings imply positive sentiment.
Bulls vs Bears: EQH Investment Factors
EQH presents a classic value-versus-value-trap debate. The bull case rests on a deeply discounted forward PE of 5.2x, a Q4 earnings turnaround, strong buybacks, and unanimous analyst optimism. The bear case highlights persistent TTM losses, declining revenue, extreme leverage, and a 1-year stock decline of 18.3%. The single most important tension is whether the Q4 2025 profitability recovery is sustainable or just a temporary reprieve from volatile insurance earnings. If the company can deliver on the $12.21 EPS estimate, the stock is dramatically undervalued; if not, the negative equity and revenue decline could lead to further downside. Currently, the evidence slightly favors the bull case given the low forward PE and strong cash position, but the risk of earnings disappointment is high.
Bullish
- Forward PE of 5.2x is deeply undervalued: EQH trades at a forward PE of 5.18x, far below the diversified insurance sector average of ~12x. This implies the market is pricing in significant earnings recovery, but if realized, the stock offers substantial upside.
- Strong capital return via buybacks: Recent news highlights major share repurchases, signaling management confidence. With a payout ratio of -27.2% (negative due to TTM losses), buybacks provide EPS tailwinds and support shareholder value.
- Q4 2025 profitability turnaround: Net income swung to $215M in Q4 2025 from losses in Q2 and Q3, with EPS of $0.71. Operating margin improved to 10.5% from negative levels earlier in the year, indicating cost controls are taking effect.
- Massive cash buffer of $12.96B: EQH holds $12.96B in cash, providing ample liquidity to weather market volatility and fund capital returns. This reduces bankruptcy risk and supports the dividend yield of 2.64%.
Bearish
- TTM net loss and negative EPS: EQH reported a trailing EPS of -$0.097 and a net margin of -11.8%, reflecting persistent unprofitability. The Q4 recovery may be temporary, and the company has posted losses in 3 of the last 4 quarters.
- Revenue decline of 9.5% YoY: Q4 2025 revenue fell to $3.28B from $3.62B a year ago, a 9.5% drop. The erratic revenue pattern (swinging from $1.45B to $3.9B) highlights lumpy insurance income and lack of predictable growth.
- Extreme leverage with negative equity: Debt-to-equity of -88.7 indicates negative shareholders' equity, common in insurance but still risky. The balance sheet is heavily leveraged, and any adverse claims could strain solvency.
- Stock down 18.3% over one year: Despite a 20.7% three-month rally, EQH is down 18.3% over the past year, underperforming the S&P 500's 19.1% gain. The 52-week low of $35.20 is 22.8% below the current price, indicating lingering bearish sentiment.
EQH Technical Analysis
EQH is in a sustained downtrend over the past year, with a 1-year price change of -18.33%. The current price of $45.61 sits at 81.4% of its 52-week range (low $35.20, high $56.04), indicating it is closer to the low end but has recovered from the March 2026 lows. This positioning suggests the stock may be in a recovery phase but remains well below its highs, reflecting lingering bearish sentiment. Over the last three months, the stock has rallied 20.69%, significantly outperforming the S&P 500's 13.56% gain, while the one-month change of +9.67% also outpaces the market's -1.25%. This short-term momentum is diverging from the negative 1-year trend, potentially signaling a trend reversal or a mean-reversion bounce. The relative strength versus the S&P 500 over 1 month is +10.92%, confirming near-term outperformance. The 52-week low of $35.20 serves as key support, while the 52-week high of $56.04 is the primary resistance. A breakout above $56.04 would signal a strong reversal, while a breakdown below $35.20 could indicate further downside. With a beta of 1.094, EQH is slightly more volatile than the market, meaning it tends to amplify market moves by about 9.4%.
Beta
1.09
1.09x market volatility
Max Drawdown
-37.0%
Largest decline past year
52-Week Range
$35-$55
Price range past year
Annual Return
-9.5%
Cumulative gain past year
| Period | EQH Return | S&P 500 |
|---|---|---|
| 1m | +8.6% | +1.0% |
| 3m | +21.9% | +7.9% |
| 6m | +0.5% | +8.5% |
| 1y | -9.5% | +20.1% |
| ytd | -0.4% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EQH Fundamental Analysis
Revenue in the most recent quarter (Q4 2025) was $3.277 billion, down 9.5% year-over-year from $3.621 billion in Q4 2024. The multi-quarter trend shows significant volatility: Q1 2025 revenue was $3.904 billion, Q2 2025 fell to $2.362 billion, Q3 2025 dropped further to $1.450 billion, and Q4 2025 rebounded to $3.277 billion. This erratic pattern reflects lumpy insurance and investment income. The Retirement segment, which generates the majority of revenue, is likely driving the fluctuations. The negative YoY growth in Q4 raises concerns about top-line momentum, though the sequential improvement from Q3 is positive. Net income in Q4 2025 was $215 million, a sharp recovery from losses in Q2 and Q3 2025 (-$349 million and -$1.309 billion, respectively). Gross margin in Q4 2025 was 88.07%, up from 67.25% in Q4 2024, indicating improved cost management. However, operating margin was 10.50% in Q4 2025, down from 33.06% in Q4 2024, reflecting higher operating expenses. The company has been unprofitable on a trailing twelve-month basis (TTM net income negative), but the Q4 profitability suggests a turnaround. The debt-to-equity ratio is -88.68, which is unusual and likely due to negative shareholders' equity (common in insurance companies with large liabilities). Free cash flow TTM is $737 million, but Q4 2025 operating cash flow was negative $80 million, partly due to working capital changes. The company has $12.96 billion in cash, providing ample liquidity. ROE is 18.65%, which is strong for the industry, but the negative equity base distorts this metric. Overall, the balance sheet is heavily leveraged but supported by substantial cash reserves.
Quarterly Revenue
$3.3B
2025-12
Revenue YoY Growth
-9.50%
YoY Comparison
Gross Margin
88.07%
Latest Quarter
Free Cash Flow
$737000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EQH Overvalued?
Since net income is negative on a TTM basis (EPS of -$0.097), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 1.22x, while the forward PE (based on estimated EPS of $12.21) is 5.18x. The gap between the negative trailing PE and the positive forward PE implies the market expects a sharp earnings recovery. The PS ratio of 1.22x is below the industry average for diversified insurance (typically 1.5-2.0x), suggesting a discount. However, the negative net margin of -11.83% indicates the company is currently unprofitable, so the PS discount may be warranted. The forward PE of 5.18x is extremely low relative to the sector average of around 12x, implying the market is pricing in significant earnings growth or a recovery. Historically, EQH's trailing PE has ranged from -25x to +63x over the past five years. The current trailing PE of -9.87x is near the bottom of its historical range, reflecting the recent losses. The forward PE of 5.18x is near the low end of its historical PE band (which has been as high as 63x), suggesting the market is pricing in a recovery but not exuberance. The low valuation could indicate a value opportunity if the earnings recovery materializes, or it could reflect structural concerns.
PE
-9.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~64x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-85.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: EQH's primary financial risk is its negative shareholders' equity (debt-to-equity of -88.7), which is typical for insurers but amplifies leverage. The company has posted a TTM net loss of -$0.097 per share, and net margin is -11.8%, indicating persistent unprofitability. Revenue is highly volatile, swinging from $1.45B in Q3 2025 to $3.9B in Q1 2025, making earnings predictability low. Operating cash flow was negative $80M in Q4 2025, though free cash flow TTM is $737M. The $12.96B cash buffer mitigates near-term liquidity risk, but the negative equity base means any large unexpected liability could be problematic.
Market & Competitive Risks: EQH trades at a forward PE of 5.2x, which is a deep discount to the sector average of 12x, but this low multiple may reflect structural concerns about earnings quality. The stock's beta of 1.094 indicates slightly higher market correlation, so a broad market downturn could amplify losses. The 1-year stock decline of 18.3% versus the S&P 500's 19.1% gain shows persistent underperformance. Regulatory changes in the insurance and retirement space could impact fee income, and competition from larger asset managers like BlackRock could pressure AllianceBernstein's margins. The limited analyst coverage (only 2 analysts) means the stock is less efficiently priced, increasing volatility.
Worst-Case Scenario: If EQH fails to sustain its Q4 2025 profitability and returns to losses, the stock could retest its 52-week low of $35.20, representing a 22.8% decline from the current price of $45.61. In a severe scenario, if the company reports a large unexpected loss or regulatory action, the stock could fall to the historical max drawdown of -37%, implying a price near $28.70. This would represent a 37% loss from current levels. The bear case is amplified by the negative equity base and revenue volatility, which could trigger analyst downgrades and further selling.
FAQ
The primary risk is earnings sustainability: EQH has posted losses in 3 of the last 4 quarters, and the Q4 2025 profit may be temporary. Financial risk is elevated due to negative shareholders' equity (debt-to-equity of -88.7), which amplifies leverage. Revenue risk is high due to erratic quarterly swings (from $1.45B to $3.9B in 2025), making forecasting difficult. Market risk is moderate with a beta of 1.094, meaning the stock amplifies market moves by about 9.4%. Additionally, limited analyst coverage (only 2 analysts) leads to less efficient pricing and higher volatility. The most severe risk is a return to losses, which could drive the stock to the 52-week low of $35.20, a 22.8% decline from current levels.
The 12-month outlook is mixed. The base case (50% probability) sees the stock trading in the $45-$55 range, assuming EPS of $12.21 and a forward PE of 5-6x. The bull case (30% probability) targets $55-$60 if earnings exceed estimates and the PE expands to 10x. The bear case (20% probability) sees the stock falling to $35-$40 if profitability fails to sustain. The most likely scenario is the base case, as the market will need multiple quarters of consistent earnings to re-rate the stock. The consensus analyst estimate of $12.21 EPS implies significant upside, but the lack of explicit price targets makes the forecast uncertain. Key catalysts include the next earnings report and any changes in buyback activity.
EQH appears undervalued based on forward earnings, with a forward PE of 5.18x compared to the diversified insurance sector average of ~12x. The trailing PS ratio of 1.22x is also below the industry range of 1.5-2.0x. However, the negative TTM net margin of -11.8% and negative trailing PE of -9.87x indicate the company is currently unprofitable, so the low multiples may be warranted. The forward PE implies the market expects a sharp earnings recovery to $12.21 EPS. Historically, EQH's trailing PE has ranged from -25x to +63x, so the current forward PE is near the low end of its historical band. Overall, the stock is undervalued if the earnings recovery occurs, but fairly valued if losses persist.
EQH is a high-risk, high-reward buy for investors who believe the Q4 2025 earnings turnaround is sustainable. The forward PE of 5.18x is deeply undervalued relative to the sector average of 12x, and the consensus EPS estimate of $12.21 implies a forward PE of just 3.7x. However, the company has negative TTM EPS of -$0.097 and revenue declined 9.5% YoY in Q4. The stock is suitable for value investors with a 12-24 month horizon who can tolerate volatility. If the earnings recovery materializes, the upside is significant; if not, the stock could fall to the 52-week low of $35.20, a 22.8% downside. The unanimous analyst bullishness and strong cash position provide some comfort, but the lack of price targets and limited coverage add uncertainty.
EQH is better suited for medium-term investment (12-24 months) given its turnaround nature and earnings volatility. The stock has a beta of 1.094, making it slightly more volatile than the market, and its 1-year decline of 18.3% shows it can be a poor short-term hold. The dividend yield of 2.64% provides some income, but the payout ratio is negative due to TTM losses, so dividend growth is uncertain. For long-term investors, the deep value thesis depends on a sustained earnings recovery, which may take several quarters to confirm. Short-term traders could capitalize on the recent momentum (20.7% gain in 3 months), but the risk of a reversal is high. A minimum holding period of 12 months is recommended to allow the earnings story to develop.